Single nucleotide polymorphisms (SNPs) in pathways influencing lymph node (LN) metastasis and estrogen receptor (ER) status in breast cancer may partially explain inter-patient variability in prognosis. We examined 154 SNPs in 12 metastasisrelated genes for associations with breast cancer risk, stratified by LN and ER status, in European-American (EA) and African-American (AA) women. Two-thousand six hundred and seventy-one women enrolled in the Women's Circle of Health Study were genotyped. Pathway analyses were conducted using the adaptive rank truncated product (ARTP) method, with p ARTP 0.10 as significant. Multi-allelic risk scores were created for the ARTP-significant gene(s). Single-SNP and risk score associations were modeled using logistic regression, with false discovery rate (FDR) P-value adjustment. Although single-SNP associations were not significant at p FDR < 0.05, several genes were significant in the ARTP analyses. In AA women, significant ARTP gene-level associations included CDH1 with LNþ (p ARTP ¼ 0.10; multi-allelic OR ¼ 1.13, 95%CI 1.07-1.19, p FDR ¼ 0.0003) and SIPA1 with ERÀ breast cancer (p ARTP ¼ 0.10; multi-allelic OR ¼ 1.16, 95%CI 1.02-1.31, p FDR ¼ 0.03). In EA women, MTA2 was associated with overall breast cancer risk (p ARTP ¼ 0.004), regardless of ER status, and with LNÀ disease (p ARTP ¼ 0.01). Also significant were SATB1 in ERÀ (p ARTP ¼ 0.03; multi-allelic OR ¼ 1.12, 95%CI 1.05-1.20, p FDR ¼ 0.003) and KISS1 in LNÀ (p ARTP ¼ 0.10; multi-allelic OR ¼ 1.18, 95%CI 1.08-1.29, p FDR ¼ 0.002) analyses. Among LNþ cases, significant ARTP associations were observed for SNAI1, CD82, NME1, and CTNNB1 (multi-allelic OR ¼ 1.09, 95%CI 1.04-1.14, p FDR ¼ 0.001). Our findings suggest that variants in several metastasis genes may affect breast cancer risk by LN or ER status, although verification in larger studies is required.
INTRODUCTION
Breast cancer prognosis is excellent when diagnosed and treated at an early stage, but is poorer when metastatic disease is present. The presence of axillary lymph node (LN) metastases at diagnosis is a strong risk factor for future recurrence and poorer prognosis. Once metastasized to distant sites, breast cancer is generally considered incurable and the majority of breast cancer-associated mortality results from metastatic disease [1] . Breast cancer mortality rates are higher among African-American (AA) women compared to European-American (EA) women, for reasons that are not fully understood. AA women tend to present with breast cancer at a younger age, with more aggressive tumor characteristics and a greater likelihood of disease progression and recurrence [2, 3] . It is therefore critical to identify mechanisms of metastasis, particularly those that may differentially affect AA and EA patients.
Inherited genetic variation in metastasis-associated genes might partially explain inter-patient variability in successful metastatic dissemination and colonization [4] . A great number of metastasisassociated genes have been identified, including those involved in epithelial-mesenchymal transition (EMT), metastasis suppressor genes, and others [5] .
EMT has been hypothesized as a mechanism by which tumor cells acquire metastatic potential, and genes involved in this process include E-cadherin (CDH1), Snail (SNAI1), and b-catenin (CTNNB1) [6] . SATB homeobox 1 (SATB1) is a genome organizing protein, which has been shown to affect expression of many genes involved in metastasis, including EMTrelated genes [7] . Metastasis suppressor genes are those that can inhibit metastatic formation without affecting primary tumor growth, and include BRMS1, CDH1, CD82/KAI1, KISS1, and NME1 [8] . These genes belong to diverse pathways, including gene transcription, cell adhesion, extracellular matrix remodeling, and apoptosis. Metastasis-associated 1 family members (MTA1, MTA2, and MTA3) are part of estrogen receptor (ER) signaling pathways and also interact with the EMT-related genes SNAI1 and CDH1 [9] . Finally, the metastasis efficiency modifying gene SIPA1 alters cell adhesion [10] and promotes metastasis in vivo [11] .
The purpose of this study was to examine common genetic variants in metastasis-related genes for associations with breast cancer risk, stratified by ER and LN status, and likelihood of ERÀ and LNþ tumors in both EA and AA women, using a combination of single-SNP and gene-based analyses. We selected 12 metastasis-associated genes (BRMS1, CDH1, CD82/ KAI1, CTNNB1, KISS1, MTA1, MTA2, MTA3, NME1, SATB1, SIPA1, and SNAI1) for analysis, focusing on those with few or no previously published studies in breast cancer.
MATERIALS AND METHODS

Study Population
The Women's Circle of Health Study (WCHS) is an ongoing case-control study designed to examine the role of genetic and non-genetic factors in relation to risk of breast cancer in AA and EA women. The study design, enrollment criteria, and collection of biospecimens and questionnaire data have previously been described in detail [12, 13] . Eligible cases were women who self-identified as AA or EA, were 20-75 yr of age at diagnosis, had no previous history of cancer other than non-melanoma skin cancer, were diagnosed with primary, incident, histologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS), and were English speaking. In New York City, cases were identified through collaborating hospitals in Manhattan, Brooklyn, Bronx, and Queens, and in New Jersey, rapid case ascertainment using the State Cancer Registry was conducted. Controls were identified contemporaneously using random digit dialing and had the same inclusion criteria as cases, but with no history of any cancer diagnosis other than non-melanoma skin cancer. Controls were frequency matched to cases by selfreported race, 5-yr age categories, and telephone exchange (New York City) or county of residence (New Jersey). In New Jersey, AA controls were also invited to participate through community recruitment events [14] . Following agreement to participate, in-person interviews were conducted to complete informed consent and an extensive epidemiologic questionnaire. Blood and/or saliva samples were collected for later extraction of DNA. Tumor characteristics were abstracted from pathology reports.
This study was approved by the Institutional Review Boards at Roswell Park Cancer Institute (RPCI), the Rutgers Cancer Institute of New Jersey (CINJ), the Icahn School of Medicine at Mount Sinai, and the participating hospitals in New York City.
DNA Sample Preparation
Blood and saliva were collected as sources of genomic DNA, which was isolated from blood using FlexiGene TM DNA isolation kits (Qiagen, Inc., Valencia, CA) and from Oragene TM (DNA Genotek, Inc., Kanata, Ontario, Canada) saliva sample collection kits, according to the respective manufacturer's protocols. Genomic DNA was evaluated and quantitated by Nanodrop UV-spectrometer (Thermo Fisher Scientific, Inc., Wilmington, DE) and PicoGreenbased fluorometric assay (Molecular Probes, Invitrogen, Inc., Carlsbad, CA), and stored at À808C until analysis.
SNP Selection
SNPs for the studied genes were chosen using the SNPInfo candidate gene SNP selection pipeline Table S1 ).
Genotyping and Quality Control
Genotype and quality control/assurance methods have been described in detail previously [13] . Genotyping was conducted on all participants who were enrolled in the study through June 2011 and had sufficient DNA available for analysis. SNPs were genotyped using the Illumina GoldenGate assay (Illumina, Inc., San Diego, CA), with 5% duplicates and two sets of in-house trio samples included for quality control purposes. The concordance among blind duplicate pairs was >99.9%. The average successful genotyping rate for each sample and each SNP was >95%. As shown in Supplementary Table S1, 22 SNPs were excluded from further analyses because they were monomorphic (n ¼ 1), violated HardyWeinberg equilibrium (P < 0.00001; n ¼ 8), or had low call rate (<98%) in EA and/or AA controls (n ¼ 9), or had MAF <5% in both EA and AA controls (n ¼ 4), leaving 132 SNPs for analysis.
Genetic Ancestry Estimate
A previously validated panel of 100 ancestry informative markers (AIMs) was also genotyped to ascertain genetic ancestry and control for population admixture [16] . Ninety-five AIMs were successfully genotyped and, based on this genotype data, estimates of European and African ancestry were obtained using the STRUCTURE program [17] . We excluded 41 women with self-reported race as "other" and 12 women with !85% estimated ancestry discordant with their self-reported race (n ¼ 11 in AAs and n ¼ 1 in EAs). Proportion of EA genetic ancestry was included as a continuous covariate in statistical analyses.
Statistical Analysis
The final dataset included 2,671 women: 658 EA cases, 649 EA controls, 621 AA cases, and 743 AA controls. ER and LN status was available for 943 and 975 cases, respectively. All analyses were conducted for EA and AA participants separately. Demographic variables and tumor characteristics were compared between groups using Chi-squared, Fisher's exact, or t-tests, as appropriate. Genotype and allele frequencies were compared between EA and AA controls using Chi-squared tests, and a Bonferroni correction was applied to adjust for multiple comparisons.
Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for 132 SNPs in association with the study outcomes (risk of breast cancer in all cases, risk of breast cancer limited to invasive cases, risk of breast cancer stratified by LN and ER status, and case-case comparisons of LN and ER status). For each SNP, codominant, dominant, recessive, and additive genetic models were tested, using the homozygous common genotype in the EA group as the reference category. Age and proportion of EA genetic ancestry were chosen a priori as covariates for single-SNP analyses. All analyses were performed separately in AA and EA women, using the same genotype as reference category to facilitate comparisons between the two groups. False discovery rate testing was implemented to control for multiple comparisons [18] . Chi-squared and t-tests, logistic regression, and false discovery rate analyses were performed using SAS version 9.3.
To consider all markers jointly, pathway analyses were conducted using the adaptive rank truncated product method (ARTP). The ARTP method is a genebased approach to pathway analysis that can confer a statistical power advantage in situations in which the causal variant is located in genes with fewer SNPs within a pathway, because it limits the effect of many SNPs in the larger gene(s) with null associations [19] . SNPs with MAF <0.05 in either EA (n ¼ 22) or AA (n ¼ 1) control groups were excluded from ARTP analysis in that group, leaving a total of 110 and 131 SNPs available for analysis in EA and AA participants, respectively. LD statistics generated for all SNP pairs in EA and AA controls were used to further filter SNPs in strong LD, defined as r 2 >0.80 between any two markers. For each pair or group of SNPs in strong LD, the SNP with the strongest single-SNP association was retained. This resulted in a final set of 87 independent SNPs for EA participants and 122 independent SNPs for AA participants. For power considerations, SNPs with variant homozygous genotype frequencies 10% were collapsed to combine the heterozygous and variant homozygous genotype categories.
The ARTP method relies on user-defined pathways. To identify interaction networks between the 12 genes we selected for genotyping, we employed the GeneMANIA gene interaction prediction server (www. genemania.org) [20] , using the default weighting method. We considered those genes that interacted with each other to form a pathway. The ARTP method was then used to obtain gene and pathway P values for associations with each outcome. Permutation P values were obtained by permuting the outcome vector (i.e., case-control status, ER status, or LN status, as appropriate) 10,000 times, while adjusting for age and proportion of European ancestry, using the default truncation points. Since permutation testing is a very conservative method for controlling the family-wise Type I error rate, we chose the more liberal P 0.10 as the gene and/or pathway significance threshold. Analyses were performed using the R package "ARTP," version 2.0.4 (R Foundation for Statistical Computing, Vienna, Austria).
The ARTP method provides an overall test of whether variants in each gene or pathway are associated with risk, but it does not provide an estimate of the magnitude or direction of the association. Therefore, multi-allelic risk scores were constructed to estimate the risk of breast cancer associated with genes found to be significant in ARTP analyses [21] . For each outcome in which one or more genes were significant at p ARTP 0.10, SNPs in these significant genes were included if the additive single-SNP model OR was <0.95 or >1.05. If the additive model OR for a given SNP was between 0.95-1.05, the association was considered null and the SNP was excluded from the summary score. For each SNP, the direction of the association with its respective outcome (positive or inverse) was determined using the additive single-SNP model. SNPs with positive associations were assigned 0, 1, and 2 at-risk alleles, and SNPs with inverse associations were assigned 2, 1, and 0 at-risk alleles. For each outcome, the summary score SNPs were added together; participants missing genotype for one or more SNPs were not assigned a summary score, to avoid misclassification with respect to number of at-risk alleles.
Summary scores were included as continuous variables in logistic regression models. Age and proportion of European ancestry were included as covariates in minimally adjusted models. Participant and tumor characteristics that were significant at P < 0.05 in EA or AA comparisons were included as additional covariates in fully adjusted models. P values derived from the logistic regression models were adjusted for multiple comparisons using the FDR method.
RESULTS
Selected participant characteristics are shown in Table 1 . When the case group was restricted to those with invasive tumors, the distribution of characteristics between cases and controls was similar among both EA and AA participants (data not shown). When compared by ER and LN status, characteristics were generally similar for both EA and AA cases. LNÀ cases tended to be older than LNþ cases in both ancestral groups. Among AA cases, women who were LNþ were significantly more likely to be premenopausal than those who were LNÀ (data not shown).
Genotype and allele frequencies were compared between EA and AA controls and results are shown in Supplementary Table S2 . For most of the SNPs we measured, genotype and allele frequencies were significantly different between the groups, after Bonferroni correction for multiple comparisons.
Results of single-SNP analyses, under the additive and dominant models, for comparisons by ER status and LN status are shown in Supplementary Tables S3  and S4 , respectively. After FDR adjustment, none of the associations remained significant.
Using GeneMANIA, we found that, by including the ESR1 (ERa) gene, all of the metastasis-associated genes selected for this study could be linked, as shown in Supplementary Figure S1 . We therefore considered the 12 genes included in this study to be components of a "metastasis pathway" for ARTP analysis. The log 10 -transformed gene and pathway P values for each outcome are shown in Figure 1 ; the raw P values are provided in Supplementary  Table S5 .
ARTP Results in EA Women
In EA women ( Figure 1A ), the overall pathway was significant only when all cases and controls were compared (p ARTP ¼ 0.10). In the analysis of all cases versus controls and when restricted to cases with invasive tumors versus controls, the MTA2 gene was highly significant (p ARTP ¼ 0.004 and p ARTP ¼ 0.01, respectively). Risk of LNþ disease was significantly associated with SNAI1 (p ARTP ¼ 0.10), CD82 (p ARTP ¼ 0.05), NME1 (p ARTP ¼ 0.10), and CTNNB1 (p ARTP ¼ 0.09). When LNÀ cases were compared to controls, the KISS1 (p ARTP ¼ 0.10) and MTA2 (p ARTP ¼ 0.01) genes were significant. In case-case analysis, positive LN status was significantly associated with the SNAI1 (p ARTP ¼ 0.01) and CTNNB1 (p ARTP ¼ 0.06) genes. When stratified by ER status, the MTA2 gene (p ARTP ¼ 0.02) was significantly associated with risk of ERþ breast cancer, while the MTA2 (p ARTP ¼ 0.08) and SATB1 (p ARTP ¼ 0.03) genes were significantly associated with risk of ERÀ breast cancer. None of the genes were significant in case-case analysis.
ARTP Results in AA Women
In AA women ( Figure 1B) , fewer significant associations were observed. Risk of LNþ breast cancer was significantly associated with the CDH1 gene (p ARTP ¼ 0.10). In case-case analysis, SIPA1 was significantly associated with negative ER status (p ARTP ¼ 0.09) and when compared to controls (p ARTP ¼ 0.10). None of the overall pathways were significant, nor were genes in any of the other outcomes.
Multi-Allelic Risk Score Results in EA Women
In EA women, risk scores made from two SNPs in MTA2 were associated with increased risk of breast cancer among all cases and when limited to invasive breast cancer in fully adjusted models ( 
Multi-Allelic Risk Score Results in AA Women
In AA women, the multi-allelic risk score composed of 19 SNPs in the CDH1 gene was significantly associated with increased risk of LNþ breast cancer ( 
DISCUSSION
In this study, although no single-SNP association remained significant after correction for multiple comparisons, the gene-based ARTP analyses, which are implicitly controlled for multiple comparisons via permutation testing, revealed several significant gene-level associations in EA (MTA2 with overall, ERþ, ERÀ, and LNÀ breast cancer; SATB1 with ERÀ Pathway and gene-level permutation P values were obtained by permuting the response vector 10,000 times for each outcome, using default truncation points. Permutation P values are shown on the log scale; Àlog(P) ! 1.0 (equivalent to P 0.10) was considered significant. breast cancer; KISS1 with LNÀ breast cancer; and SNAI1, CTNNB1, CD82, and NME1 with LNþ breast cancer) and AA (CDH1 with LNþ breast cancer; SIPA1 with ERÀ breast cancer) participants.
MTA2 has histone deacetylase activity and is a subunit of Mi-2/NuRD chromatin remodeling complexes [22] . By interacting with Twist1, a transcription factor that is a master regulator of EMT, MTA2 mediates repression of E-cadherin [23] . Furthermore, by binding to ERa and acting as a repressor, MTA2 modulates acetylation and transcriptional activity of ERa [24] . One of the two SNPs included in the genebased analysis, rs11231156, is predicted by RegulomeDB [25] to be likely to affect transcription binding and is linked to expression of a gene target (RegulomeDB score 1f).
SATB1 is a nuclear matrix and scaffold attachment region-binding protein [26] that acts as a genome organizer [27] . Gene expression profiling of the metastatic breast cancer cell line MDA-MB-231 has shown that, among others, SATB1 downregulates CTNNB1, CDH1, BRMS1, CD82, KISS1, and NME1 [7] . One study examining SNPs in SATB1 with respect to breast cancer found that homozygous carriers of the À3600T/À3363A/À2984C haplotype had improved overall survival [28] . We genotyped rs1475469, which is in strong LD with À2984C>T (rs6762753; r 2 ¼ 0.96; CEU population, 1000 Genomes Phase 3 data). Furthermore, using the GRASP (Genome-wide Repository of Associations between SNPs and Phenotypes) database [29] , we found that two SNPs included in the gene-based analysis, rs4129096 and rs9714119, were associated with breast cancer mortality at P ¼ 0.01 and P ¼ 0.0006, respectively [30] .
The transcription factor SNAI1 is a key developmental EMT regulator and transcriptional repressor of E-cadherin and ERa [31] [32] [33] . Two of the variants in the gene-based analysis, rs6020177 and rs6091080, are predicted by RegulomeDB to affect binding (scores of 1f and 2b, respectively). While the role of SNAI1 Multi-allelic scores were constructed for each outcome that had one or more ARTP-significant genes; only SNPs in significant genes were included. Unconditional logistic regression was used to test associations between each score and its corresponding outcome, with FDR P-value correction. SNPs were excluded from score construction if the additive model OR was between 0.95 and 1.05. For AA women, CDH1 rs16958383 was excluded. For EA women, SNAI1 rs1543442; CD82 rs934178, rs1981994, rs6485550, rs3758813, and rs3781753; KISS1 rs4951315 and rs12568353; and SATB1 rs9852969, rs9849722, rs12106735, and rs6550461 were excluded. ER ¼ estrogen receptor; FDR ¼ false discovery rate; LN ¼ lymph node; OR ¼ odds ratio; CI ¼ confidence interval.
variants in LN metastasis has not previously been examined, the variant allele of the nonsynonymous SNP rs4647958 has been associated with reduced overall risk of breast cancer among women with older age at first pregnancy [34] . The transcriptional co-factor and structural protein b-catenin (CTNNB1) links E-cadherin (CDH1) to the actin cytoskeleton and is the central protein of the Wnt signaling pathway, which regulates cell proliferation, differentiation, and apoptosis [35] . Two variants (rs4135385 and rs1307263) have previously been examined using a candidate gene approach, although not in EA or AA populations, with conflicting results as to breast cancer risk [36, 37] .
CD82, NME1, and KISS1 are metastasis suppressor genes, which inhibit metastatic formation without affecting primary tumor growth. CD82/KAI1 is a cell surface glycoprotein that interacts with the Duffy antigen chemokine receptor, an endothelial cell surface protein, to anchor tumor cells to vascular endothelial cells, inducing tumor cell senescence and suppressing metastatic spread [38] .
NME1 (also known as NM23-H1) is regulated by p53 and estrogen [39, 40] , and affects expression of genes involved in cell migration, apoptosis, and angiogenesis through its interaction with ERa [41] . Two promoter region SNPs (rs2302254 and rs16949649), both included in our analysis, have been implicated in an increased risk of relapse, metastasis, and breast cancer-specific mortality [42] and are predicted by RegulomeDB to be likely to affect binding (scores of 2b and 1f, respectively).
KISS1 appears to be involved in the NF-kB and ER signaling pathways. Induction of KISS1 expression results in decreased expression of Snail2, a transcription factor involved in EMT, and an increase in E-cadherin expression [43] , indicating that one metastasis suppressive function of KISS1 is to inhibit EMT and maintain the epithelial phenotype. One SNP we examined, rs3795573, was predicted to affect binding (RegulomeDB score 2b). One prior study found that rs5780218 was significantly associated with risk of breast cancer among Mexican patients [44] , but this SNP is not in LD with any of the ones we included.
CDH1 is a tumor suppressor and metastasis suppressor, the loss of which promotes tumor cell invasiveness and induces EMT in experimental models. E-cadherin (CDH1) is a calcium-dependent cell-cell adhesion protein that is crucial for maintaining cell polarity, epithelial architecture and structural integrity, and preserving cell-cell interactions [35] . Several studies have examined polymorphisms in CDH1 in relation to breast cancer risk or prognosis, with conflicting results [34, [45] [46] [47] [48] [49] [50] , although few data exist for AA populations. Four of the SNPs included in the gene-based analysis are predicted to affect binding by RegulomeDB (rs7188750, 1b; rs9941051, 1f; rs10431923, 1f; rs9940250, 2b).
SIPA1 catalyzes the hydrolysis of guanosine triphosphate to guanosine diphosphate and has been shown to regulate cell adhesion [10] . Several SIPA1 variants have been studied, mainly in white populations, but associations with breast cancer risk and survival have not been consistent [51, 52] . In one study, rs931127 (promoter region) and rs746429, a synonymous SNP (Ala920Ala), were associated with increased likelihood of having nodal metastases at diagnosis, while a nonsynonymous SNP, rs3741378 (Ser182Phe), was associated with ER-and PR-negative tumors [53] . We previously observed an increased likelihood of the HER2-expressing subtype, which includes ERÀ tumors, in women with the variant rs3741378 genotype, although the estimate was imprecise due to small numbers [54] . Here, we found that SIPA1 variants, including rs3741378, were associated with ERÀ breast cancer, in case-control and case-case analyses, in AA women.
Strengths of this study include the use of in-person interviews to gather detailed information on family history and hormone-related variables, which permitted greater control of potential confounding variables. In addition, this study used a panel of 100 AIMs to address population stratification within categorical racial groups, a well-known source of confounding due to admixture in genetic epidemiology studies. AIMs allow for estimation of individual ancestral proportions, which can then be included as a covariate in multivariate models. African populations are known to be more genetically diverse than non-African populations [55] . Admixture with individuals of European ancestry has further contributed to genetic diversity in AAs. The panel we selected has been shown to reliably estimate the proportion of European ancestry in AA individuals, using data from the Black Women's Health Study [16] . Since these AIMs were designed to capture admixture in AAs, it is unclear how well they capture admixture in EAs; however, since there is less admixture in EA groups, confounding is less likely to have affected our results.
Our study is limited, however, by the inclusion of only 12 genes; it is likely that other metastasis-related genes contribute to breast cancer development, particularly LNþ tumors, perhaps by interacting with the genes we have investigated here. We examined common variants by identifying a set of tag SNPs within each gene, but there may be other important genetic contributions that we were unable to examine because of sample size limitations, such as rare variation and gene-environment interactions. We also restricted our definition of gene region to AE5 kb upstream and downstream. However, since SNPs that affect gene expression may be found at distances further than this, it is possible that SNPs with important functional effects were missed by our definition.
We did not have recurrence or survival data available to examine long-term outcomes, which may be important for understanding the effects of these variants on metastasis, and our sample size precluded stratification by tumor subtype. Furthermore, we were unable to compare early-stage and metastatic breast cancer cases, due to sample size limitations; our study contained only one EA and four AA stage IV cases. Instead, we examined associations with LN status, a strong prognostic variable, and ER status, since ERÀ tumors are typically more aggressive and have a worse prognosis. Although ER status and LN status were missing for 26% and 12% of all cases and invasive tumor cases, respectively, participant characteristics were generally similar between those with and without known ER and LN status, indicating that our estimates were unlikely to be biased by missingness for these features.
Our study is also limited by the lack of validation using an independent population, as well as the fact that the sample sizes within subgroups prohibit separation into testing and training sets for crossvalidation strategies. Finally, given the small numbers of participants in our subgroup analyses, our study may be underpowered to detect small effect sizes for the genes we examined. We therefore cannot rule out the possibility of false-negative findings. For these reasons, additional large, well-powered studies with long-term outcome data are needed both to replicate the findings we report herein as well as to further investigate the contribution of genetic variation to metastasis.
In conclusion, we found evidence suggesting that variants in different metastasis-related genes may affect risk of breast cancer, by LN and ER status, in EA and AA women. Several promising associations were identified that require confirmation and, in particular, investigation of SNP effects on recurrence and survival. Additional studies are needed to better understand the genetic basis for the development of breast cancer in different ancestral groups, particularly as it relates to aggressive tumor subtypes and metastatic potential.
